NCT00331357

Brief Summary

The objective of this study is to describe a paediatric population presenting an acute idiopathic thrombocytopenic purpura (ITP) and their evolution during their therapy in the region Pays de la Loire. The study will particularly evaluate the quality of life of these patients and their parents. The secondary objectives are to identify the predictive factors of the complications, the repetitions and the chronicity of the ITP, to estimate the principal parameters of the economic cost of therapy of the children suffering from ITP according to the protocol of therapy, set up in the region Pays de la Loire and the constitution of a blood sample collection which allow a better understanding of the physiopathology of this disease. It is about a prospective, multicentric clinical epidemiologic study of a paediatric cohort. Patients: 100 children from 0 to 17,99 years suffering from a first discovered ITP. The patients are not included if they present a serious, intercurrent, stabilized chronic pathology or not likely to modify the quality of life of the child and if they present a pathology other than the thrombopenia bringing into play the vital prognosis within a time lower than one year. These patients will be followed for 6 months according to the diagnosis of their ITP. During the 6 months follow-up of each patient, the study will not carry out more consultations, nor more blood tests than the usual follow-up of a child suffering from ITP. On the other hand, in addition to the J0 questionnaire, it will be requested to the patient and to his family to fill in the questionnaires of quality of life and way of life during the consultations of J8, 1 month, 3 months and 6 months. A check-up of autoimmunity at 6 months will be carried out if the thrombopenia persists (this check-up is usual and not-specific to the study). At the time of the blood test for the control of the platelets at J0 and 6 months, an additional blood sample will be carried out: 5 ml are taken for the children of an age ≤ at 2 years, 10 ml from 2 to 4 years and 15 ml of blood for the children of an age \> at 4 years. These blood samples are intended for the constitution of a blood sample collection. The protocol of therapy of the children suffering from ITP is homogeneous in all centers, this protocol being a consensus established by the network of Oncopaediatrics of the Pays de la Loire. The instituted treatment will be in function of the gravity of the ITP expressed in 4 stages: Stage I: Platelets \> 20 gigas/L and absence of clinical signs. Stage II: Platelets \> 10 gigas/L and hemorrhagic signs: haematomas, petechias or occasional epistaxis without repercussion on the daily life. Stage III: moderate. Platelets \> 10.000/mm3 and epistaxis with gauze pluggings or mucous lesions. Stage IV: severe. Platelets ≤ 10.000/mm3 or fall of 2 grs/dl of haemoglobin with bleedings: epistaxis, melaena or haemorrhages requiring a blood transfusion or an hospitalization and important changes in the activities of the daily life. Stages I and II do not receive any treatment and benefit from a simple monitoring. Stages III benefit from either a corticosteroid treatment (Méthylprednisolone or Prednisone) at the dose of 4 mg/kg and per day in 2 intervals during 4 days (maximal dose of 100 mg/day) or a monitoring according to the appreciation of the clinician. Stages IV profit in first intention from a treatment by Méthylprednisolone or Prednisone at the dose of 4 mg/kg and per day in 2 intervals during 4 days (maximal dose of 100 mg/jour). The therapeutic attitude and the stadification belong to a regional consensus, established before the study, but each one can decide to apply a treatment according to the gravity of the clinical state of the child.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2006

Typical duration for all trials

Geographic Reach
1 country

7 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 29, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 31, 2006

Completed
1 day until next milestone

Study Start

First participant enrolled

June 1, 2006

Completed
2.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

May 31, 2006

Status Verified

May 1, 2006

First QC Date

May 29, 2006

Last Update Submit

May 29, 2006

Conditions

Keywords

acute idiopathic thrombocytopenic purpurapaediatricquality of life

Eligibility Criteria

Age0 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • children 0 to 17,99 years
  • suffering from a first discovered ITP

You may not qualify if:

  • serious, intercurrent, stabilized chronic pathology or not likely to modify the quality of life of the child
  • pathology other than the thrombopenia bringing into play the vital prognosis within a time lower than one year

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

UH of Angers

Angers, 49933, France

Location

Hospital of Cholet

Cholet, 49 325, France

Location

Hospital of La Roche Sur Yon

La Roche-sur-Yon, 85 925, France

Location

Hospital of Laval

Laval, 53 015, France

Location

Hospital of Le Mans

Le Mans, 72 037, France

Location

UH of Nantes

Nantes, 44 093, France

Location

Hosptal of Saint Nazaire

Saint-Nazaire, 44 606, France

Location

Related Publications (1)

  • Strullu M, Rakotonjanahary J, Tarral E, Savagner C, Thomas C, Mechinaud F, Reguerre Y, Poignant S, Boutet A, Bassil J, Medinger D, Quemener E, Young NL, Rachieru P, Klaassen RJ, Pellier I. Evaluation of health related quality of life in children with immune thrombocytopenia with the PedsQL 4.0 Generic Core Scales: a study on behalf of the pays de Loire pediatric hematology network. Health Qual Life Outcomes. 2013 Nov 13;11:193. doi: 10.1186/1477-7525-11-193.

Study Officials

  • Isabelle PELLIER, MD

    UH of Angers

    STUDY DIRECTOR

Central Study Contacts

isabelle PELLIER, MD

CONTACT

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

May 29, 2006

First Posted

May 31, 2006

Study Start

June 1, 2006

Study Completion

December 1, 2008

Last Updated

May 31, 2006

Record last verified: 2006-05

Locations